Clinical Report: Baseline Systemic Immune-Inflammation Index in Follicular Lymphoma

Overview

The FLIPI-SII model, incorporating the baseline systemic immune-inflammation index (SII), serves as a prognostic tool for predicting progression of disease within 24 months (POD24) and long-term outcomes in patients with grade 1–3a follicular lymphoma. This model has undergone internal and external validation.

Background

Follicular lymphoma (FL) is a common indolent non-Hodgkin lymphoma, yet it presents clinically heterogeneous behavior, with some patients experiencing early progression. The identification of reliable prognostic markers is crucial for stratifying risk. The FLIPI-SII model aims to address this need by integrating systemic immune-inflammatory status into existing prognostic frameworks.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

• The FLIPI-SII model combines baseline SII with the established FLIPI for enhanced prognostic stratification.
• Elevated baseline SII is independently associated with poorer overall survival (OS) and progression-free survival (PFS).
• FLIPI-SII has undergone both internal and multicenter external validation, supporting its generalizability.
• Prognostic information from FLIPI-SII should not be conflated with treatment selection, as its role is primarily stratification.
• POD24 is a significant clinical endpoint, indicating a high-risk subgroup with unfavorable outcomes.

Clinical Implications

The FLIPI-SII model should be regarded as a prognostic stratification tool rather than a treatment-selection model.

Conclusion

The FLIPI-SII model emphasizes the importance of systemic immune-inflammatory status in predicting patient outcomes.

Related Resources & Content

1. Yu J, Sun C, Liu Q, Wang G, Wang J, Li L, et al., Frontiers in Immunology, 2026 -- Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1–3a follicular lymphoma
2. The ASCO Post — Tumor Immune Infiltration and Disease Progression in Follicular Lymphoma
3. Blood Cancer Journal — Absence of Intrafollicular Memory CD4+ T Cells as an Indicator of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma
4. the asco post — FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
5. Blood Cancer Journal — Disease Progression at 24 Months (POD24) in Follicular Lymphoma During the Rituximab Era: Incidence, Clinicopathological Risk Factors, and Outcomes in a Danish Population-Based Study
6. Tumor Immune Infiltration and Disease Progression in Follicular Lymphoma
7. Absence of Intrafollicular Memory CD4+ T Cells as an Indicator of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma
8. FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
9. Disease Progression at 24 Months (POD24) in Follicular Lymphoma During the Rituximab Era
10. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
11. FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
12. Frontiers | Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1–3a follicular lymphoma